On August 27 and August 29, 2002, the SEC issued final rule and Form 4 amendments with respect to the accelerated filing deadline applicable to Section 16 filings, as required by the Sarbanes-Oxley Act of 2002. Effective August 29, 2002, most Form 4 transactions must be reported to the SEC before the end of the second business day following the day on which the transaction was executed. (For example, a transaction executed on Tuesday must be reported on Form 4 filed before 5:30 p.m., Washington D.C. time, on Thursday.) The new rules affect transactions subject to Section 16(a) for which the date of execution (trade date) is on or after August 29, 2002. The amendments do not affect transactions that occurred before August 29, 2002.
Who must file.
Section 16(a) of the Securities Exchange Act of 1934 requires every person who is a director, officer or 10% owner of an issuer with a class of securities registered under Section 12 of the Exchange Act to file a Form 4 with the SEC whenever there has been a change in ownership of the equity securities of that issuer.
Heres one for ya Big
Analytical evaluation of the automated galectin-3 assay on the Abbott ARCHITECT immunoassay instruments.
Galectin-3 is secreted from macrophages and binds and activates fibroblasts forming collagen. Tissue fibrosis is central to the progression of chronic heart failure CHF. We performed a European multicentered evaluation of the analytical performance of the two-step routine and Short Turn-Around-Time STAT galectin-3 immunoassay on the ARCHITECT i1000SR, i2000SR, and i4000SR (Abbott Laboratories).
We evaluated the assay precision and dilution linearity for both routine and STAT assays and compared serum and plasma, and fresh vs. frozen samples. The reference interval and biological variability were also assessed. Measurable samples were compared between ARCHITECT instruments and between the routine and STAT assays and also to a galectin-3 ELISA BG Medicine.
The total assay coefficient of variation CV% was 2.3%-6.2% and 1.7%-7.4% for the routine and STAT assays, respectively. Both assays demonstrated linearity up to 120 ng/mL. Galectin-3 concentrations were higher in plasma samples than in serum samples and correlated well between fresh and frozen samples (R=0.997), between the routine and STAT assays, between the ARCHITECT i1000 and i2000 instruments and with the galectin-3 ELISA. The reference interval on 627 apparently healthy individuals (53% male) yielded upper 95th and 97.5th percentiles of 25.2 and 28.4 ng/mL, respectively. Values were significantly lower in subjects younger than 50 years.
The galectin-3 routine and STAT assays on the Abbott ARCHITECT instruments demonstrated good analytical performance. Further clinical studies are required to demonstrate the diagnostic and prognostic potential of this novel marker in patients with CHF.
Big, this abstract was from June 2014
What are you talking about, NO EXPENSES, They are paying full staff till Sept 11 for this Quarter, Plus 300k in severance payments, You will see IMHO a very bad earnings release, Sales are gonna be way off from last Q, Hope I'm wrong, But I don't think so
No debt on the books, WHAT ARE YOU TALKING ABOUT, They owe GE OVER 5 M, do some DD before posting BS
On February 10, 2012, the Company entered into a secured term loan facility, and a term loan in the aggregate principal amount of $10.0 million was funded upon the closing of the transaction.
May 2013 Loan Amendment
In May 2013, the Company amended its loan and security agreement to allow for a three month deferral of principal payments beginning May 1, 2013 and to allow for up to an additional three months of deferral based on the Company meeting certain minimum liquidity requirements, as defined in the amendment. The Company made principal payments in March and April 2013 prior to the signing of the amendment. $$$$$$ The Company did not meet the additional liquidity requirements, as defined in the amendment, and, accordingly, principal payments resumed on August 1, 2013. The amendment also increased certain loan fees by $50,000, and amended the terms of the warrants, as discussed below.$$$$$$$
Learn how to read filings,
The interest rate in effect at June 30, 2014 was 9.25%. Interest only payments were made for the first twelve months of the loan term. Following that initial twelve month period, principal and interest payments are required to be paid on a monthly basis through maturity at September 2015.
At June 30, 2014, we have an outstanding balance of $5.2 million under the term loan facility and we are required to repay the principal monthly through maturity in September 2015. Our term loan is secured by substantially all of our assets.
Son, In plain english this means they "MUST " repay allllll of the loan by Sept 2015, You do the math, Thats $372,000 a month, Or to make it simple for you to understand $1.116,000 a quarter.
And just to let you know " maturity " means the end of the loan, Not when they have to pay back the loan.
ANYONE that post facts that you don't agree with, You label them a basher, Very sad, You just bury your heads up your you know what and Ignore the facts.
You may end up being right in the long run, But you are ignoring the current facts, One of which is this company doesn't give a rats behind about keeping shareholders informed, Maybe there's a reason, I really don't, and neither do you, All I post is what's going on right now.
You get guys like this new poster yesterday pumping pumping pumping, And let's not forget about King, GO, GO , GO.
You won't keep me from posting the facts and what I think, I do wish you all good luck. You're gonna need it
I'm in and out of this stock faster then a sailor on Friday night, who the check are you to tell me to get a life, How do you know if I don't own this stock, There is not a single poster on this forum that has posted more positive articles about GAL 3 and this company then myself, NOT ONE, ENRIQUE is the closest,
I post mostly all facts with some comments with my opinion. Why did you give that joker a pass last night when he posted b.s. about this company having no debt. H?MMMMMMMM, oh.I know why, it must have been he was pumping, and that's ok with all you longs here.
You are 100 pct correct Jess, It really makes you think something's wrong, You'll all know soon, The 10q is due out this week or next, If they announce earnings for Fri. After the bell, It'll all be over, Most likely next Wednesday pre market, But any earnings on Friday is the kiss of death.
You were right all along about the pump of the stock before the offering, That sucked in a lot of folks that have been under water ever since, VERY SAD, Those poor people were sucked in by this company who knew all along what would happen on the following months, Iay all of this at the feet of the BOD of this company.
It's all the bashers fault, RIGHT LONGS, What a joke
Cookie. You don't suspect anything ???, at 3:59 it was at . 47, at 3:59:50 someone sold 149 shares and dropped the price to . 44 and you're alright with that, you think there's no manipulation ??
•Gal-3 has been considered a cardiac fibrosis and remodeling marker.
•Gal-3 correlates highly with renal function.
•Gal-3 correlates highly with Cystatin C.
•The prognostic value of Gal-3 in HF declines when adjusted by renal function.
•Gal-3 might possibly be considered a cardio-renal biomarker.
Galectin-3 (Gal-3) has been associated with cardiac remodeling and heart failure HF prognosis. Renal function is also a well known HF prognostic indicator. The link between renal insufficiency, HF, and Gal-3 is not completely elucidated.
Methods and results
We explored the association between Gal-3 and renal function in a cohort of 876 consecutive ambulatory patients with HF mean age: 68 years; mean left ventricular ejection fraction LVEF 36%. 52.2% had HF etiology of ischemic heart disease. Circulating Gal-3 was highly correlated with estimated glomerular filtration rate eGFR, calculated with either the chronic kidney disease-epidemiology CKD-EPI equation r = −0.64 or the CKD-EPI-cystatin-C equation r = −0.59 and with Cystatin-C levels r = 0.70 after adjusting for age, sex, New York Heart Association NYHA functional class, LVEF, and HF etiology all p
Patients were stratified by CKD-EPI-eGFR In these strata, Gal-3 significantly increased This was independent of NYHA functional class Gal-3 was associated with mortality in univariate analyses, but after adjusting for , the hazard ratios were for all cause death, for cardiovascular death. Similar results were obtained with eGFRs calculated with the CKD-EPI-cystatin-C equation.
Circulating Gal-3 was highly associated with renal function in outpatients with HF. The value of Gal-3 for HF prognosis declined after adjusting for renal function.
Jess, This for all intents and purposes is a one trick pony right now , what else is there ?? without Abbott's Gal 3 Automated Assay there will be no money to go forward with the likes of CardioScore, and anything new that would come from the BioImage Study, There is nothing else in their pipeline.
Without cash and absolutely no way to raise cash, and that includes the current Galectin 3 test, In this current position, There are no other options IMHO, They would have to basically sign their rights away to the BioImage Study to raise much needed cash, No , Without Abbott's Clearance this company IMHO would be finished.
I know I'm gonna get he11 for posting this ,But it's the truth IMO
King, instead of whining all the time, why don't you post where you think the company is going, for starters, why not read my last post, tell what you think, the only thing you ever post is, go, going to $10., or its about to go up, but you never explain why, in my last post I explain why I think the way I do, why don't you try doing that some time.
Just taking a shot in the dark with bgmd, you've got a better chance at a casino or the lottery, I hope you don't call yourself an investor. You have no retort to me about reading my post and to post your own thoughts about why this stock will go up or down, you've got no idea what you're doing.
Call him out?? No need to do that, every time he post he shows his ignorance , I actually hope everyone on this board makes money, and plenty of it.
As for earnings release, Ahhhh how about next Wednesday, Will that work for you, if not let me know, maybe w can have it the following Wednesday, let me know